BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020;9:682-720. [PMID: 33442540 DOI: 10.1159/000509424] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Liu DM, Leung TW, Chow PK, Ng DC, Lee RC, Kim YH, Mao Y, Cheng YF, Teng GJ, Lau WY. Clinical consensus statement: Selective internal radiation therapy with yttrium 90 resin microspheres for hepatocellular carcinoma in Asia. Int J Surg 2022;102:106094. [PMID: 35662438 DOI: 10.1016/j.ijsu.2021.106094] [Reference Citation Analysis]
2 Jin A, Yang Y, Su X, Yang W, Liu T, Chen W, Li T, Ding L, Wang H, Wang B, Pan B, Zhou J, Fan J, Yang X, Guo W. High serum soluble CD155 level predicts poor prognosis and correlates with an immunosuppressive tumor microenvironment in hepatocellular carcinoma. Clinical Laboratory Analysis. [DOI: 10.1002/jcla.24259] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Li C, Lu X, Xiao J, Chan CWH. 'We can bear it!' Unpacking barriers to hepatocellular carcinoma screening among patients with hepatitis B: A qualitative study. J Clin Nurs 2021. [PMID: 34816510 DOI: 10.1111/jocn.16140] [Reference Citation Analysis]
4 Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2021. [PMID: 34780081 DOI: 10.1111/liv.15101] [Reference Citation Analysis]
5 Zhang W, Chen Z, Xue C, Zhang Y, Wu L, Zhu J, Xuan S, Tian J, Pang Z. The Applicability of ADA, AFU, and LAC in the Early Diagnosis and Disease Risk Assessment of Hepatitis B-Associated Liver Cirrhosis and Hepatocellular Carcinoma. Front Med (Lausanne) 2021;8:740029. [PMID: 34557505 DOI: 10.3389/fmed.2021.740029] [Reference Citation Analysis]
6 Ju S, Zhou C, Yang C, Wang C, Liu J, Wang Y, Huang S, Li T, Chen Y, Bai Y, Yao W, Xiong B. Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center. Front Oncol 2022;11:835889. [DOI: 10.3389/fonc.2021.835889] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
7 Meng L, Xu KX, Zhao MX, Li K, Zhu K, Yuan DW, Wang HN, Dai PG, Yan R. Nucleolar protein 6 promotes cell proliferation and acts as a potential novel prognostic marker for hepatocellular carcinoma. Chin Med J (Engl) 2021;134:2611-8. [PMID: 34561331 DOI: 10.1097/CM9.0000000000001655] [Reference Citation Analysis]
8 Li XY, Shen Y, Zhang L, Guo X, Wu J. Understanding initiation and progression of hepatocellular carcinoma through single cell sequencing. Biochim Biophys Acta Rev Cancer 2022;:188720. [PMID: 35304295 DOI: 10.1016/j.bbcan.2022.188720] [Reference Citation Analysis]
9 Ke Q, Xin F, Fang H, Zeng Y, Wang L, Liu J. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review. Front Immunol 2022;13:913464. [DOI: 10.3389/fimmu.2022.913464] [Reference Citation Analysis]
10 Zhang J, Huang S, Xu Y, Wu J. Diagnostic Accuracy of Artificial Intelligence Based on Imaging Data for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol 2022;12:763842. [PMID: 35280776 DOI: 10.3389/fonc.2022.763842] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Sun J, Liu C, Wang N, Jiang D, Zhang F, Shi J, Cheng S. All-Trans-Retinoic Acid Plus Oxaliplatin/Fluorouracil/Leucovorin for Advanced Hepatocellular Carcinoma with Pulmonary Metastasis: A Multicenter Retrospective Study. CMAR 2022;Volume 14:1663-70. [DOI: 10.2147/cmar.s354170] [Reference Citation Analysis]
12 Kudo M. Surveillance, Diagnosis, and Treatment Outcomes of Hepatocellular Carcinoma in Japan: 2021 Update. Liver Cancer 2021;10:167-80. [PMID: 34239807 DOI: 10.1159/000516491] [Reference Citation Analysis]
13 Fu J, Cao Z, Zhang J, Chen Q, Wang Y, Wang S, Fang X, Xu X. Identification of two immune-related risk score signatures through integrated analysis of multi-omics data in hepatocellular carcinoma. Gene 2022;829:146519. [PMID: 35447248 DOI: 10.1016/j.gene.2022.146519] [Reference Citation Analysis]
14 Zheng Z, Guan R, Jianxi W, Zhao Z, Peng T, Liu C, Lin Y, Jian Z, Wu YS. Microvascular Invasion in Hepatocellular Carcinoma: A Review of Its Definition, Clinical Significance, and Comprehensive Management. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/9567041] [Reference Citation Analysis]
15 Yan J, Li T, Deng M, Fan H. Ruptured Hepatocellular Carcinoma: What Do Interventional Radiologists Need to Know? Front Oncol 2022;12:927123. [DOI: 10.3389/fonc.2022.927123] [Reference Citation Analysis]
16 Feng JK, Sun JX, Liu ZH, Gu JW, Chen ZH, Liu C, Guo WX, Shi J, Cheng SQ. Efficacy and Safety of Transarterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma Associated with Bile Duct Tumor Thrombus: A Real-World Retrospective Cohort Study. Cancer Manag Res 2021;13:3551-60. [PMID: 33953609 DOI: 10.2147/CMAR.S307065] [Reference Citation Analysis]
17 Zhong BY, Wang WS, Zhang S, Zhu HD, Zhang L, Shen J, Zhu XL, Teng GJ, Ni CF. Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists. J Clin Transl Hepatol 2021;9:521-7. [PMID: 34447681 DOI: 10.14218/JCTH.2021.00049] [Reference Citation Analysis]
18 Chan LL, Chan SL. Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma. Cancers (Basel) 2022;14:1526. [PMID: 35326677 DOI: 10.3390/cancers14061526] [Reference Citation Analysis]
19 Qu S, Zhang X, Wu Y, Meng Y, Pan H, Fang Q, Hu L, Zhang J, Wang R, Wei L, Wu D. Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study. Front Oncol 2022;12:874473. [DOI: 10.3389/fonc.2022.874473] [Reference Citation Analysis]
20 Su TH, Hsu SJ, Kao JH. Paradigm shift in the treatment options of hepatocellular carcinoma. Liver Int 2021. [PMID: 34515412 DOI: 10.1111/liv.15052] [Reference Citation Analysis]
21 Zhu J, Fang P, Wang C, Gu M, Pan B, Guo W, Yang X, Wang B. The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma. Cancer Med 2021;10:7977-87. [PMID: 34605616 DOI: 10.1002/cam4.4312] [Reference Citation Analysis]
22 Wu Z, Tang H, Wang L, Jin X, Lei Z, Yang P, Zhou J. Postoperative survival analysis of hepatocellular carcinoma patients with liver cirrhosis based on propensity score matching. BMC Surg 2022;22:103. [PMID: 35313836 DOI: 10.1186/s12893-022-01556-5] [Reference Citation Analysis]
23 Mo Q, Liu Y, Zhou Z, Li R, Gong W, Xiang B, Tang W, Yu H. Prognostic Value of Aspartate Transaminase/Alanine Transaminase Ratio in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma Undergoing Hepatectomy. Front Oncol 2022;12:876900. [PMID: 35664791 DOI: 10.3389/fonc.2022.876900] [Reference Citation Analysis]
24 Jin AL, Zhang CY, Zheng WJ, Xian JR, Yang WJ, Liu T, Chen W, Li T, Wang BL, Pan BS, Li Q, Cheng JW, Wang PX, Hu B, Zhou J, Fan J, Yang XR, Guo W. CD155/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis. Clin Transl Med 2022;12:e794. [PMID: 35384345 DOI: 10.1002/ctm2.794] [Reference Citation Analysis]
25 Li QJ, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, Chen MS, Shi M. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. J Clin Oncol 2021;:JCO2100608. [PMID: 34648352 DOI: 10.1200/JCO.21.00608] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Lee S, Jung J, Park JH, Kim SY, Choi J, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Park HH, Kim JH, Yoon SM. Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients. BMC Cancer 2022;22:175. [PMID: 35172769 DOI: 10.1186/s12885-022-09263-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Li X, Yao Q, Liu C, Wang J, Zhang H, Li S, Cai P. Macrotrabecular-Massive Hepatocellular Carcinoma: What Should We Know? JHC 2022;Volume 9:379-87. [DOI: 10.2147/jhc.s364742] [Reference Citation Analysis]
28 Zhou L, Wang M, Guo H, Hou J, Zhang Y, Li M, Wu X, Chen X, Wang L. Integrated Analysis Highlights the Immunosuppressive Role of TREM2+ Macrophages in Hepatocellular Carcinoma. Front Immunol 2022;13:848367. [DOI: 10.3389/fimmu.2022.848367] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Zhang WB, Hou SZ, Chen YL, Mao F, Dong Y, Chen JG, Wang WP. Deep Learning for Approaching Hepatocellular Carcinoma Ultrasound Screening Dilemma: Identification of α-Fetoprotein-Negative Hepatocellular Carcinoma From Focal Liver Lesion Found in High-Risk Patients. Front Oncol 2022;12:862297. [PMID: 35720017 DOI: 10.3389/fonc.2022.862297] [Reference Citation Analysis]
30 Wang JC, Hou JY, Chen JC, Xiang CL, Mao XH, Yang B, Li Q, Liu QB, Chen J, Ye ZW, Peng W, Sun XQ, Chen MS, Zhou QF, Zhang YJ. Development and validation of prognostic nomograms for single large and huge hepatocellular carcinoma after curative resection. Eur J Cancer 2021;155:85-96. [PMID: 34371445 DOI: 10.1016/j.ejca.2021.07.009] [Reference Citation Analysis]
31 Lyu LH, Zhang CY, Yang WJ, Jin AL, Zhu J, Wang H, Liu T, Wang BL, Cheng JW, Yang XR, Guo W. Hsa_circ_0003945 promotes progression of hepatocellular carcinoma by mediating miR-34c-5p/LGR4/β-catenin axis activity. J Cell Mol Med 2022. [PMID: 35170199 DOI: 10.1111/jcmm.17243] [Reference Citation Analysis]
32 Xia F, Ndhlovu E, Zhang M, Chen X, Zhang B, Zhu P. Ruptured Hepatocellular Carcinoma: Current Status of Research. Front Oncol 2022;12:848903. [DOI: 10.3389/fonc.2022.848903] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
33 Liu L, Xie S, Teng Y, Deng Z, Chen K, Liu H, Huo R, Liang X, Guo P, Yang D, Ma L, Xiang B, Li L, Zhong J. Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC. Front Oncol 2022;11:783339. [DOI: 10.3389/fonc.2021.783339] [Reference Citation Analysis]
34 Ogasawara S, Choo SP, Li JT, Yoo C, Wang B, Lee D, Chow PKH. Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia-Pacific Region: A Review and Multidisciplinary Expert Opinion. Cancers (Basel) 2021;13:2626. [PMID: 34071818 DOI: 10.3390/cancers13112626] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Gil-Gómez A, Rojas Á, Liu CH, Gallego-Duran R, Muñoz-Hernandez R, Fassina G, Pontisso P, Ampuero J, Romero-Gómez M. Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid- and long-term prediction of hepatocellular carcinoma among cirrhotic patients. World J Gastroenterol 2021; 27(48): 8343-8356 [DOI: 10.3748/wjg.v27.i48.8343] [Reference Citation Analysis]
36 Renzulli M, Mottola M, Coppola F, Cocozza MA, Malavasi S, Cattabriga A, Vara G, Ravaioli M, Cescon M, Vasuri F, Golfieri R, Bevilacqua A. Automatically Extracted Machine Learning Features from Preoperative CT to Early Predict Microvascular Invasion in HCC: The Role of the Zone of Transition (ZOT). Cancers 2022;14:1816. [DOI: 10.3390/cancers14071816] [Reference Citation Analysis]
37 Lin N, Lin Y, Xu J, Liu D, Li D, Meng H, Gallant MA, Kubota N, Roy D, Li JS, Gorospe EC, Sherman M, Gish RG, Abou-Alfa GK, Nguyen MH, Taggart DJ, Van Etten RA, Hoshida Y, Li W. A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma. Hepatol Commun 2022. [PMID: 35244350 DOI: 10.1002/hep4.1918] [Reference Citation Analysis]
38 Wu JY, Yin ZY, Bai YN, Chen YF, Zhou SQ, Wang SJ, Zhou JY, Li YN, Qiu FN, Li B, Yan ML. Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. J Hepatocell Carcinoma 2021;8:1233-40. [PMID: 34676181 DOI: 10.2147/JHC.S332420] [Reference Citation Analysis]
39 Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX, Finn RS. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 2021. [PMID: 34764464 DOI: 10.1038/s41571-021-00573-2] [Reference Citation Analysis]
40 Kudo M. Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy. Cancers (Basel) 2021;13:5475. [PMID: 34771637 DOI: 10.3390/cancers13215475] [Reference Citation Analysis]
41 Ji GW, Fan Y, Sun DW, Wu MY, Wang K, Li XC, Wang XH. Machine Learning to Improve Prognosis Prediction of Early Hepatocellular Carcinoma After Surgical Resection. J Hepatocell Carcinoma 2021;8:913-23. [PMID: 34414136 DOI: 10.2147/JHC.S320172] [Reference Citation Analysis]
42 Ji K, Zhu H, Wu W, Li X, Zhan P, Shi Y, Sun J, Li Z. Tumor Response and Nomogram-Based Prognostic Stratification for Hepatocellular Carcinoma After Drug-Eluting Beads Transarterial Chemoembolization. JHC 2022;Volume 9:537-51. [DOI: 10.2147/jhc.s360421] [Reference Citation Analysis]
43 Qin L, Liu X, Lan L, Lv X. ROCK2 Polymorphism and Expression Contribute to Increased Susceptibility and Poor Prognosis in Hepatocellular Carcinoma. IJGM 2022;Volume 15:1295-306. [DOI: 10.2147/ijgm.s343968] [Reference Citation Analysis]
44 Xu X, Huang A, Guo DZ, Wang YP, Zhang SY, Yan JY, Wang XY, Cao Y, Fan J, Zhou J, Fu XT, Shi YH. Integration of Inflammation-Immune Factors to Build Prognostic Model Predictive of Prognosis and Minimal Residual Disease for Hepatocellular Carcinoma. Front Oncol 2022;12:893268. [PMID: 35756674 DOI: 10.3389/fonc.2022.893268] [Reference Citation Analysis]
45 Huang Q, Chen Y, Lin K, Sun C, Zheng S, Chen J, Wang Y, Zhou Y, Zhou W, Liu J, Zeng Y. Redefining Hepatocellular Carcinoma Staging Systems Based on the Bile Duct Invasion Status: A Multicenter Study. Front Oncol 2021;11:673285. [PMID: 34722235 DOI: 10.3389/fonc.2021.673285] [Reference Citation Analysis]
46 Sun T, Li R, Qiu Y, Shen S, Wang W. New Thresholds for AFP and Des-γ-Carboxy Prothrombin in Chronic Liver Disease Depending on the Use of Nucleoside Analogs and an Integrated Nomogram. Int J Gen Med 2021;14:6149-65. [PMID: 34611429 DOI: 10.2147/IJGM.S335400] [Reference Citation Analysis]
47 Cai Z, Su X, Qiu L, Li Z, Li X, Dong X, Wei F, Zhou Y, Luo L, Chen G, Chen H, Wang Y, Zeng Y, Liu X. Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion. Mol Cancer 2021;20:164. [PMID: 34903219 DOI: 10.1186/s12943-021-01467-8] [Reference Citation Analysis]
48 Su K, Gu T, Xu K, Wang J, Liao H, Li X, Wen L, Song Y, Zhong J, He B, Liu X, He J, Liu Y, Li Q, Feng X, Chen S, Yang B, Huang W, Jin H, Luo X, Hu T, Chen J, Wu Z, Lu S, Zhang J, Rao M, Xie Y, Wang J, Zhu X, Chen L, Li B, Su S, Yang X, Wang J, Zeng H, Wang P, Yan M, Chen X, He K, Han Y. Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study. Hepatol Int 2022. [PMID: 35729469 DOI: 10.1007/s12072-022-10339-2] [Reference Citation Analysis]
49 Sun T, Chen L, Kan X, Ren Y, Cao Y, Zhang W, Lu H, Zheng C. A Comparative Analysis of Efficacy of Apatinib Combined with Transarterial Chemoembolization and Transarterial Chemoembolization Alone in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Oncol 2022;2022:1255133. [PMID: 35356254 DOI: 10.1155/2022/1255133] [Reference Citation Analysis]
50 Wang Z, Zhong Y, Zhang Z, Zhou K, Huang Z, Yu H, Liu L, Liu S, Yang H, Zhou J, Fan J, Wu L, Sun Y. Characteristics and Clinical Significance of T-Cell Receptor Repertoire in Hepatocellular Carcinoma. Front Immunol 2022;13:847263. [PMID: 35371059 DOI: 10.3389/fimmu.2022.847263] [Reference Citation Analysis]
51 Wen L, Weng S, Yan C, Ye R, Zhu Y, Zhou L, Gao L, Li Y. A Radiomics Nomogram for Preoperative Prediction of Early Recurrence of Small Hepatocellular Carcinoma After Surgical Resection or Radiofrequency Ablation. Front Oncol 2021;11:657039. [PMID: 34026632 DOI: 10.3389/fonc.2021.657039] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Sun HC, Zhu XD. Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview. Front Oncol 2021;11:772195. [PMID: 34869008 DOI: 10.3389/fonc.2021.772195] [Reference Citation Analysis]
53 Liao B, Liu L, Wei L, Wang Y, Chen L, Cao Q, Zhou Q, Xiao H, Chen S, Peng S, Li S, Kuang M. Innovative Synoptic Reporting With Seven-Point Sampling Protocol to Improve Detection Rate of Microvascular Invasion in Hepatocellular Carcinoma. Front Oncol 2021;11:726239. [PMID: 34804920 DOI: 10.3389/fonc.2021.726239] [Reference Citation Analysis]
54 Minami Y, Minami T, Ueshima K, Yagyu Y, Tsurusaki M, Okada T, Hori M, Kudo M, Murakami T. Three-Dimensional Radiological Assessment of Ablative Margins in Hepatocellular Carcinoma: Pilot Study of Overlay Fused CT/MRI Imaging with Automatic Registration. Cancers (Basel) 2021;13:1460. [PMID: 33806751 DOI: 10.3390/cancers13061460] [Reference Citation Analysis]
55 Su Y, Liu Y, Hsiao C, Hsu C, Chen L. Trial Designs for Integrating Novel Therapeutics into the Management of Intermediate-Stage Hepatocellular Carcinoma. JHC 2022;Volume 9:517-36. [DOI: 10.2147/jhc.s220978] [Reference Citation Analysis]
56 Chen J, Chen S, Zhou Y, Wang S, Wu W. Efficacy and Safety of Huaier Granule as an Adjuvant Therapy for Cancer: An Overview of Systematic Reviews and Meta-Analyses. Integr Cancer Ther 2022;21:15347354221083910. [PMID: 35245981 DOI: 10.1177/15347354221083910] [Reference Citation Analysis]
57 Sun L, Cai H, Zhou T, Xiang H, Long L. Verbascoside enhances radiosensitivity of hepatocellular carcinoma cells through regulating miR-101-3p/Wee1 axis. Drug Dev Res 2022. [PMID: 35080031 DOI: 10.1002/ddr.21914] [Reference Citation Analysis]
58 Dong S, Zhuang X, Yangyang L, Yan L, Houbo D, Song W, Meng X, Tiejun L. Efficacy and safety of acupuncture combined with Chinese herbal medicine in the treatment of primary liver cancer: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e27497. [PMID: 34622883 DOI: 10.1097/MD.0000000000027497] [Reference Citation Analysis]
59 Li Y, Pan Y, Lin X, Hou J, Hu Z, Xu L, Zhou Z, Zhang Y, Chen M, Hu D. Development and Validation of a Prognostic Score for Hepatocellular Carcinoma Patients in Immune Checkpoint Inhibitors Therapies: The Hepatocellular Carcinoma Modified Gustave Roussy Immune Score. Front Pharmacol 2021;12:819985. [PMID: 35237150 DOI: 10.3389/fphar.2021.819985] [Reference Citation Analysis]
60 Xu C, Jiang D, Tan B, Shen C, Guo J. Preoperative diagnosis and prediction of microvascular invasion in hepatocellularcarcinoma by ultrasound elastography. BMC Med Imaging 2022;22:88. [PMID: 35562688 DOI: 10.1186/s12880-022-00819-0] [Reference Citation Analysis]
61 Su B, Bei Z, Pei H, Xie X, Sun Z, Chen Q, Cao H, Liu X. Generation of a nanobody-alkaline phosphatase heptamer fusion for ratiometric fluorescence immunodetection of trace alpha fetoprotein in serum. Int J Biol Macromol 2022;201:507-15. [PMID: 35063488 DOI: 10.1016/j.ijbiomac.2022.01.056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
62 Zhang JX, Yan HT, Ding Y, Liu J, Liu S, Zu QQ, Shi HB. Low Psoas-Muscle index is associated with decreased survival in hepatocellular carcinoma treated with transarterial chemoembolization. Ann Med 2022;54:1562-9. [PMID: 35639492 DOI: 10.1080/07853890.2022.2081872] [Reference Citation Analysis]
63 Cai M, Huang W, Huang J, Shi W, Guo Y, Liang L, Zhou J, Lin L, Cao B, Chen Y, Zhou J, Zhu K. Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study. Front Immunol 2022;13:848387. [PMID: 35300325 DOI: 10.3389/fimmu.2022.848387] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Shen Y, Huang C, Zhu X, Xu M, Chen Z, Tan C, Zhou J, Fan J, Sun H. The Safety Profile of Hepatectomy Following Preoperative Systemic Therapy with Lenvatinib Plus Anti-PD-1 Antibodies Versus Hepatectomy Alone in Patients With Hepatocellular Carcinoma. Annals of Surgery Open 2022;3:e163. [DOI: 10.1097/as9.0000000000000163] [Reference Citation Analysis]
65 Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2021;15:1295-307. [PMID: 34624198 DOI: 10.1080/17474124.2021.1991792] [Reference Citation Analysis]
66 Wang G, Zhang W, Chen J, Luan X, Wang Z, Wang Y, Xu X, Yao S, Guan Z, Tian J, Lu S, Xu B, Ma G. Pretreatment Metabolic Parameters Measured by 18F-FDG PET to Predict the Pathological Treatment Response of HCC Patients Treated With PD-1 Inhibitors and Lenvatinib as a Conversion Therapy in BCLC Stage C. Front Oncol 2022;12:884372. [PMID: 35719917 DOI: 10.3389/fonc.2022.884372] [Reference Citation Analysis]
67 Zhou J, Han F, Zhang H, Sun Y, Li Z, Wang T, Zhang K. Aptamer-Based Triple Serum Fluorescence Intensity Assay: A Novel and Feasible Method for the Clinical Diagnosis of Primary Hepatic Carcinoma. Front Oncol 2022;12:897775. [DOI: 10.3389/fonc.2022.897775] [Reference Citation Analysis]
68 Lu Z, Liu R, Wang Y, Jiao M, Li Z, Wang Z, Huang C, Shi G, Ke A, Wang L, Fu Y, Xia J, Wen H, Zhou J, Wang X, Ye D, Fan J, Chu Y, Cai J. Ten-eleven translocation-2 inactivation restrains IL-10-producing regulatory B cells to enable antitumor immunity in hepatocellular carcinoma. Hepatology 2022. [PMID: 35243663 DOI: 10.1002/hep.32442] [Reference Citation Analysis]
69 Chen K, Wei W, Liu L, Deng ZJ, Li L, Liang XM, Guo PP, Qi LN, Zhang ZM, Gong WF, Huang S, Yuan WP, Ma L, Xiang BD, Li LQ, Zhong JH. Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice. Cancer Immunol Immunother 2021. [PMID: 34559308 DOI: 10.1007/s00262-021-03060-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Qian Y, Li L, Ma L, Ji R, Ying S, Zhou J, Fu L, Yang G. Validation of the hepatocellular carcinoma early detection screening algorithm Doylestown and aMAP in a cohort of Chinese with cirrhosis. J Clin Lab Anal 2022;:e24296. [PMID: 35218083 DOI: 10.1002/jcla.24296] [Reference Citation Analysis]
71 Liu HT, Jiang MJ, Deng ZJ, Li L, Huang JL, Liu ZX, Li LQ, Zhong JH. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. Front Oncol 2021;11:737497. [PMID: 34745958 DOI: 10.3389/fonc.2021.737497] [Reference Citation Analysis]
72 Fu S, Lai H, Huang M, Li Q, Liu Y, Zhang J, Huang J, Chen X, Duan C, Li X, Wang T, He X, Yan J, Lu L. Multi-task deep learning network to predict future macrovascular invasion in hepatocellular carcinoma. EClinicalMedicine 2021;42:101201. [PMID: 34917908 DOI: 10.1016/j.eclinm.2021.101201] [Reference Citation Analysis]
73 Wang S, Chen S, Jin M, Hu M, Huang W, Jiang Z, Yang J, Zhang Y, Wu H, Hu Y, He W, Fu L. Diagnostic and prognostic value of serum Chitinase 3-like protein 1 in hepatocellular carcinoma. J Clin Lab Anal 2022;:e24234. [PMID: 35034385 DOI: 10.1002/jcla.24234] [Reference Citation Analysis]
74 Vitale A, Farinati F, Finotti M, Di Renzo C, Brancaccio G, Piscaglia F, Cabibbo G, Caturelli E, Missale G, Marra F, Sacco R, Giannini EG, Trevisani F, Cillo U, Associazione Italiana Per Lo Studio Del Fegato Aisf Hcc Special Interest Group, Italian Liver Cancer Ita Li Ca Study Group. Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. Cancers (Basel) 2021;13:1673. [PMID: 33918125 DOI: 10.3390/cancers13071673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Yang F, Xu G, Huang J, Yin Y, Xiang W, Zhong B, Li W, Shen J, Zhang S, Yang J, Sun HP, Wang W, Zhu X. Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response. Front Immunol 2022;13:847601. [DOI: 10.3389/fimmu.2022.847601] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Khan AR, Wei X, Xu X. Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides. J Hepatocell Carcinoma 2021;8:1089-115. [PMID: 34522691 DOI: 10.2147/JHC.S318070] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
77 Zheng K, Liao A, Yan L, Yang J, Wen T, Wang W, Li B, Wu H, Jiang L. Hepatic Resection Combined with Intraoperative Radiofrequency Ablation Versus Hepatic Resection Alone for Selected Patients with Moderately Advanced Multifocal Hepatocellular Carcinomas. Ann Surg Oncol 2022. [PMID: 35441310 DOI: 10.1245/s10434-022-11757-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
78 Wei H, Jiang H, Qin Y, Wu Y, Lee JM, Yuan F, Zheng T, Duan T, Zhang Z, Qu Y, Chen J, Chen Y, Ye Z, Yao S, Zhang L, Yang T, Song B. Comparison of a preoperative MR-based recurrence risk score versus the postoperative score and four clinical staging systems in hepatocellular carcinoma: a retrospective cohort study. Eur Radiol 2022. [PMID: 35554652 DOI: 10.1007/s00330-022-08811-6] [Reference Citation Analysis]
79 Qin L, Qin J, Lv X, Yin C, Zhang Q, Zhang J. MIF promoter polymorphism increases peripheral blood expression levels, contributing to increased susceptibility and poor prognosis in hepatocellular carcinoma. Oncol Lett 2021;22:549. [PMID: 34093770 DOI: 10.3892/ol.2021.12810] [Reference Citation Analysis]
80 Qiong L, Jie Z, Zhong Z, Wen S, Jun Z, Liping L, Jinkui C. Detection of hepatocellular carcinoma in a population at risk: iodine-enhanced multidetector CT and/or gadoxetic acid-enhanced 3.0 T MRI. BMJ Open 2022;12:e058461. [PMID: 35177466 DOI: 10.1136/bmjopen-2021-058461] [Reference Citation Analysis]
81 Lin K, Wei F, Huang Q, Lai Z, Zhang J, Chen Q, Jiang Y, Kong J, Tang S, Lin J, Chen Y, Chen J, Zeng Y. Postoperative Adjuvant Transarterial Chemoembolization Plus Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma: a Multicentre Retrospective Study. JHC 2022;Volume 9:127-40. [DOI: 10.2147/jhc.s352480] [Reference Citation Analysis]
82 Galun D, Mijac D, Filipovic A, Bogdanovic A, Zivanovic M, Masulovic D. Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. JPM 2022;12:149. [DOI: 10.3390/jpm12020149] [Reference Citation Analysis]
83 Li X, Fu Z, Zhong J, Cao K, Chen X, Ding N, Liu L, Zhai J, Qu Z. Coexistence of situs inversus totalis and hepatocellular carcinoma: A series of nine cases and a literature review. Journal of Interventional Medicine 2022;5:46-9. [DOI: 10.1016/j.jimed.2021.12.007] [Reference Citation Analysis]
84 Shi Z, Yang W, Tang H, Li X. Risk factors of infection after transarterial chemoembolization for hepatocellular carcinoma: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e25851. [PMID: 34011050 DOI: 10.1097/MD.0000000000025851] [Reference Citation Analysis]
85 Ju S, Zhou C, Hu J, Wang Y, Wang C, Liu J, Yang C, Huang S, Li T, Chen Y, Bai Y, Yao W, Xiong B. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09451-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
86 Xiao LS, Hu CY, Cui H, Li RN, Hong C, Li QM, Huang CY, Dong ZY, Zhu HB, Liu L. Splenomegaly in predicting the survival of patients with advanced primary liver cancer treated with immune checkpoint inhibitors. Cancer Med 2022. [PMID: 35599583 DOI: 10.1002/cam4.4818] [Reference Citation Analysis]
87 Liao R, Wei X, Che P, Yin K, Liu L. Nomograms Incorporating the CNLC Staging System Predict the Outcome of Hepatocellular Carcinoma After Curative Resection. Front Oncol 2022;11:755920. [DOI: 10.3389/fonc.2021.755920] [Reference Citation Analysis]
88 Wang S, Cui J, Fan Q, Gan J, Liu C, Wang Y, Yang T, Wang J, Yang C. Reversible and Highly Ordered Biointerfaces for Efficient Capture and Nondestructive Release of Circulating Tumor Cells. Anal Chem 2022. [PMID: 35732056 DOI: 10.1021/acs.analchem.2c01743] [Reference Citation Analysis]
89 Yu HM, Wang K, Feng JK, Lu L, Qin YC, Cheng YQ, Guo WX, Shi J, Cong WM, Lau WY, Dong H, Cheng SQ. Image-matching digital macro-slide-a novel pathological examination method for microvascular invasion detection in hepatocellular carcinoma. Hepatol Int 2022. [PMID: 35294742 DOI: 10.1007/s12072-022-10307-w] [Reference Citation Analysis]
90 Lyu N, Yi JZ, Zhao M. Immunotherapy in older patients with hepatocellular carcinoma. Eur J Cancer 2021;162:76-98. [PMID: 34954439 DOI: 10.1016/j.ejca.2021.11.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Li Y, Xu C, Sun B, Zhong F, Cao M, Yang L. Piezo1 promoted hepatocellular carcinoma progression and EMT through activating TGF-β signaling by recruiting Rab5c. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-022-02574-2] [Reference Citation Analysis]
92 Xu H, Yu X, Hu J. The Risk Assessment and Clinical Research of Bile Duct Injury After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma. Cancer Manag Res 2021;13:5039-52. [PMID: 34234549 DOI: 10.2147/CMAR.S303172] [Reference Citation Analysis]
93 Sun Y, Wu L, Zhong Y, Zhou K, Hou Y, Wang Z, Zhang Z, Xie J, Wang C, Chen D, Huang Y, Wei X, Shi Y, Zhao Z, Li Y, Guo Z, Yu Q, Xu L, Volpe G, Qiu S, Zhou J, Ward C, Sun H, Yin Y, Xu X, Wang X, Esteban MA, Yang H, Wang J, Dean M, Zhang Y, Liu S, Yang X, Fan J. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell 2021;184:404-421.e16. [PMID: 33357445 DOI: 10.1016/j.cell.2020.11.041] [Cited by in Crossref: 20] [Cited by in F6Publishing: 34] [Article Influence: 10.0] [Reference Citation Analysis]
94 Aliya S, Lee H, Alhammadi M, Umapathi R, Huh YS. An Overview on Single-Cell Technology for Hepatocellular Carcinoma Diagnosis. Int J Mol Sci 2022;23:1402. [PMID: 35163329 DOI: 10.3390/ijms23031402] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Cohen O, Aleem M, Wolberink S, Perenyei MA. Giant pedunculated liver mass: primary hepatocellular carcinoma masquerading as hepatic haemangioma. BMJ Case Rep 2021;14:e242625. [PMID: 34593547 DOI: 10.1136/bcr-2021-242625] [Reference Citation Analysis]
96 Romito I, Porru M, Braghini MR, Pompili L, Panera N, Crudele A, Gnani D, De Stefanis C, Scarsella M, Pomella S, Levi Mortera S, de Billy E, Conti AL, Marzano V, Putignani L, Vinciguerra M, Balsano C, Pastore A, Rota R, Tartaglia M, Leonetti C, Alisi A. Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects. J Exp Clin Cancer Res 2021;40:364. [PMID: 34784956 DOI: 10.1186/s13046-021-02154-8] [Reference Citation Analysis]
97 Jin ZC, Chen L, Zhong BY, Zhu HD, Zeng CH, Li R, Guo JH, He SC, Deng G, Zhu XL, Ni CF, Teng GJ. Impact of COVID-19 Pandemic on Intervals and Outcomes of Repeated Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma. Front Oncol 2021;11:602700. [PMID: 34026598 DOI: 10.3389/fonc.2021.602700] [Reference Citation Analysis]